お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:中国の血液製剤業界(2020年~2027年)
市場調査レポート
商品コード
999582

中国の血液製剤業界(2020年~2027年)

China Blood Product Industry Report, 2020-2027

出版日: | 発行: ResearchInChina | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
中国の血液製剤業界(2020年~2027年)
出版日: 2021年03月19日
発行: ResearchInChina
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

中国における血液製剤のロットリリース量は、前年比12.7%増の1億131万本となり、成長を続けています。国民医療保険制度の対象となる医薬品が調整されたことにより、ほぼすべての血液製剤の臨床使用の範囲と償還率が飛躍的に拡大し、血液製剤市場はさらに拡大しています。

近年、中国では血液製剤メーカーのM&Aが活発化しています。大手企業は、主にM&Aを利用し、血漿ステーションを自前で建設して、補完された拡張モデルによって急成長しました。M&Aは彼らの長期的な戦略計画の重要な部分です。

当レポートは、中国の血液製剤業界について調査しており、市場規模、政策、現状、市場構造、需要と供給、主要企業のプロファイル、見通しなどの情報を提供しています。

目次

第1章 血液製剤

  • 定義
  • 分類
  • 組換え血液製剤
  • 産業チェーン
  • 特徴

第2章 中国の血液製剤市場

  • ポリシー
  • 現状
  • 市場構造
  • 需要と供給
    • 供給
    • 需要
  • 市場規模
  • 競争パターン

第3章 中国の血液製剤市場セグメント

  • ヒトアルブミン
    • 現状
    • 入札価格
    • 市場構造
    • 競争パターン
    • 見通し
  • 静注用ヒト免疫グロブリン(pH4)
    • 現状
    • 入札価格
    • 競争パターン
    • 見通し
  • 凝固第VIII因子
    • 現状
    • 入札価格
    • 競争パターン
    • 見通し
  • ヒトB型肝炎免疫グロブリン
    • 現状
    • 入札価格
    • 競争パターン
  • ヒト免疫グロブリン
    • 現状
    • 入札価格
    • 競争パターン
  • ヒトプロトロンビン複合体
    • 現状
    • 入札価格
    • 競争パターン
  • ヒト破傷風免疫グロブリン
    • 現状
    • 入札価格
    • 競争パターン
  • ヒト狂犬病免疫グロブリン
    • 現状
    • 入札価格
    • 競争パターン

第4章 主要企業

  • China Biologic Products (CBPO)
  • Hualan Biological Engineering Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Beijing Tiantan Biological Products
  • Guangdong Shuanglin Bio-Pharmacy
  • Jiangxi Boya Bio-Pharmaceutical
  • Weiguang Biological Products
  • Beijing Bohui Innovation Technology
  • Wuhan ZhongyuanRuide Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Product Co., Ltd.
  • Green Cross China
  • Nanyue Biopharming Corporation Ltd.

第5章 要約と予測

  • 概要
  • 開発動向
    • ブームが続く業界
    • 業界統合の加速、さらに高まる集中
    • 業界を左右する血漿採取量と血漿ステーション数
    • 徐々に増加する血漿採取量
    • 競争力を強化するための企業の新製品の研究開発への注力、血漿の包括的利用のさらなる進歩
    • ダウンストリームの需要による業界への刺激
    • 医療制度改革が深まり、医療保険制度の段階的な完成による業界の成長への貢献
    • COVID-19パンデミックによる国内企業への開発の機会
目次

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%.

Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.

The Health Commission of Yunnan Province proposed to set up 24 plasma collection stations (adding 20 new ones based on the 4 pilot ones) across the province, according to the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023) (Exposure Draft) it issued in December 2020. Currently, Shanghai Blood Products under Beijing Tiantan Biological Products has 2 pilot stations operated in Yunnan, having collected a total of around 42 tons. Also, the document indicates blood product companies that construct production bases in Yunnan will be given priority to build. With its plasma station expansion plan, Yunnan may set the pace in loosening the restrictions on new plasma stations. On one estimate, China had boasted 273 plasma collection stations by the end of 2020.

In 2020, the pandemic suspended plasma collection in China for two months, stopping collection volume growth. Chinese Academy of Medical Sciences predicted a like-on-like slump of 22%, or 1,000 tons, in plasma collection volume in the first half of 2020.

Companies with more plasma stations, such as Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products and Hualan Biological Engineering gather pace and will scramble for larger shares on the strength of their great ability to collect plasma, promising their far higher industry status. In 2019, Beijing Tiantan Biological Products, Hualan Biological Engineering, China Biologic Products and Shanghai RAAS Blood Products took a higher combined market share of up to 34.47%.

In recent years, there were an increasing number of mergers and acquisitions among blood products companies in China. Leaders roared ahead mainly by way of mergers and acquisitions, an expansion model supplemented by self-built plasma stations. Mergers and acquisitions have been a key part of their long-term strategic plans.

On January 28, 2020, Southern Shuanglin Bio-Pharmacy made an announcement that it would merge with Harbin Pacific Biopharmaceutical and restructure it, and raise funds. Southern Shuanglin Bio-Pharmacy now has 13 plasma collection stations, collecting roughly 400 tons in 2019, compared with Harbin Pacific Biopharmaceutical which owns 10 stations collecting 240 tons in 2019. Moreover, Southern Shuanglin Bio-Pharmacy and Xinjiang Deyuan Bioengineering forged a strategic partnership in which Xinjiang Deyuan Bioengineering promises to provide over 180-ton plasma for Southern Shuanglin Bio-Pharmacy every year, totaling more than 900 tons for the five years to come. Southern Shuanglin Bio-Pharmacy is thus expected to be a first-echelon player in the industry.

“China Blood Product Industry Report, 2020-2027” highlights the following:

  • China blood product industry (policy, status quo, market structure, supply & demand, market size, competitive pattern);
  • China blood product market segments (status quo, bid price, competitive pattern);
  • 13 blood product companies (operation, revenue structure, gross margin, blood product business, etc.);
  • Summary and forecast.

Table of Contents

1. Blood Products

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2. China Blood Product Market

  • 2.1 Policies
  • 2.2 Status Quo
  • 2.3 Market Structure
  • 2.4 Supply and Demand
    • 2.4.1 Supply
    • 2.4.2 Demand
  • 2.5 Market Size
  • 2.6 Competitive Pattern

3. China Blood Product Market Segments

  • 3.1 Human Albumin
    • 3.1.1 Status Quo
    • 3.1.2 Bid Price
    • 3.1.3 Market Structure
    • 3.1.4 Competitive Pattern
    • 3.1.5 Prospects
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Status Quo
    • 3.2.2 Bid Price
    • 3.2.3 Competitive Pattern
    • 3.2.4 Prospects
  • 3.3 Coagulation Factor VIII
    • 3.3.1 Status Quo
    • 3.3.2 Bid Price
    • 3.3.3 Competitive Pattern
    • 3.3.4 Prospects
  • 3.4 Human Hepatitis B Immunoglobulin
    • 3.4.1 Status Quo
    • 3.4.2 Bid Price
    • 3.4.3 Competitive Pattern
  • 3.5 Human Immunoglobulin
    • 3.5.1 Status Quo
    • 3.5.2 Bid Price
    • 3.5.3 Competitive Pattern
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Status Quo
    • 3.6.2 Bid Price
    • 3.6.3 Competitive Pattern
  • 3.7 Human Tetanus Immunoglobulin
    • 3.7.1 Status Quo
    • 3.7.2 Bid Price
    • 3.7.3 Competitive Pattern
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Status Quo
    • 3.8.2 Bid Price
    • 3.8.3 Competitive Pattern

4. Major Enterprises

  • 4.1 China Biologic Products (CBPO)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D Investment
    • 4.1.6 Blood Products Business
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.9 Xi'an Huitian Blood Products Co., Ltd.
  • 4.2 Hualan Biological Engineering Co., Ltd.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Blood Products Business
    • 4.2.7 Development Strategy
  • 4.3 Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Blood Products Business
    • 4.3.7 Development Strategy
  • 4.4 Beijing Tiantan Biological Products
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Blood Products Business
    • 4.4.7 Chengdu Rongsheng
    • 4.4.8 Dynamics
  • 4.5 Guangdong Shuanglin Bio-Pharmacy
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Gross Margin
    • 4.5.4 R&D Investment
    • 4.5.5 Blood Products Business
    • 4.5.6 Dynamics
  • 4.6 Jiangxi Boya Bio-Pharmaceutical
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Blood Products Business
    • 4.6.7 Dynamics
  • 4.7 Weiguang Biological Products
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Blood Products Business
    • 4.7.7 Development Strategy
  • 4.8 Beijing Bohui Innovation Technology
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Blood Products Business
    • 4.8.7 Development Strategy
    • 4.8.8 Dynamics
  • 4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Blood Products Business
  • 4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.10.1 Profile
    • 4.10.2 Blood Products Business
    • 4.10.3 Development Strategy
  • 4.11 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.11.1 Profile
    • 4.11.2 Blood Products Business
  • 4.12 Green Cross China
    • 4.12.1 Profile
    • 4.12.2 Blood Products Business
  • 4.13 Nanyue Biopharming Corporation Ltd.
    • 4.13.1 Profile
    • 4.13.2 Blood Products Business
    • 4.13.3 Development Strategy

5. Summary and Forecast

  • 5.1 Summary
  • 5.2 Development Trends
    • 5.2.1 The Industry Continues to Boom
    • 5.2.2 Industry Integration Speeds Up, Concentration Rises Further
    • 5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
    • 5.2.4 Plasma Collection Volume Increases Progressively
    • 5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
    • 5.2.6 Downstream Demand Stimulates the Industry
    • 5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Growth of the Industry
    • 5.2.8 COVID-19 Pandemic Brings Development Opportunities to Domestic Companies
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.